INTRODUCTION
All the patients were allowed protected weight bearing with a walking stick for three months. Prophylactic antibiotics were administered, and prophylactic low-molecularweight heparin was given subcutaneously for five weeks postoperatively. Most patients were discharged from the hospital after 5-10 days, either to their previous residences or to temporary rehabilitation hospitals.
All the patients' records, including gender, age, American Society of Anesthesiologists (ASA) class rating and fracture pattern according to Evans classification, were complete.
Reduction quality and implant position were recorded after surgery. Postoperative follow-up was undertaken at 1, 3, 6 and 12 months, and yearly thereafter. Anteroposterior and lateral plain radiographs were obtained at each visit.
The quality of fracture reduction was assessed using the measurement of the postoperative fracture gap (mm) and the Garden Alignment Index. (7) The fracture gap, which was measured using the first postoperative anteroposterior and lateral radiographs, was classified as good (0-3 mm); acceptable 
The implant position in the femoral head was recorded using Cleveland zones (8) and tip apex distance (TAD). (9) To determine the implant position in the femoral head, the anteroposterior and lateral radiographs were scanned with 
RESUlTS
The preoperative characteristics of patients who were treated with either PFNA or Gamma 3 are shown in Table I . No significant differences were found between the two groups in terms of gender, age, side of fracture, type of fracture and ASA score. (Table II) . No intraoperative complication was observed in any of the patients.
Fracture reduction was assessed using the measurement of the fracture gap and the Garden Alignment Index. The mean fracture gap in the PFNA group was significantly greater than that in the Gamma 3 group. In the PFNA group, the fracture gap measurement was < 3 mm in 51 cases, < 5 mm in 57 cases and > 5 mm in 7 cases. In the Gamma 3 group, the measurement was < 3 mm in 102 cases and < 5 mm in 22 cases, with no case having a measurement > 5 mm (Table III) . Statistical analysis between the two groups revealed a significant difference in the reduction quality, in favour of patients treated with Gamma 3.
Using the Garden Alignment Index, the reduction quality of fractures that were treated with PFNA was graded as very good in 27 cases; good in 55; acceptable in 24; and poor in 9. In fractures treated with Gamma 3, 32 cases were documented as very good; 57 as good; 25 as acceptable; and 10 as poor. The mean Garden Alignment Index of the PFNA group was similar to that of the Gamma 3 group, and statistical analysis between the two groups revealed no significant difference (Table IV) .
The implant position was recorded according to the Regardless of whether patients received PFNA or Gamma 3 fixation, there was no significant change in TAD immediately after surgery and at one month after surgery. Although, TAD decreased significantly from the time immediately after surgery to the third month after surgery, no significant decrease was observed at the twelfth month after surgery when compared to the TAD at the third month ( Table V) .
Complications that occurred during the postoperative period are summarised in Table VI 
DISCUSSION
In our study, the patients in both the PFNA and Gamma 3 groups had good outcomes, with few complications and a failure rate of 0.8%. Both PFNA and Gamma 3 have the advantages of high union rate, early postoperative mobilisation, short image intensifier and operative times, less blood loss and fewer postoperative complications. We also found PFNA and Gamma 3 osteosynthesis to be the methods Our study showed no significant differences in image intensifier time, operative time, amount of blood loss and postoperative complications between patients treated with PFNA and those treated with Gamma 3. However, Xu et al (11) reported that PFNA fixation for the treatment of intertrochanteric fractures resulted in less blood loss and shorter fluoroscopy time as compared with Gamma 3. These contradictory findings could be attributed to differences in the level of experience of the surgeons. We found both PFNA and Gamma 3 to be reliable implants for treating intertrochanteric fractures.
There were two cases of cutouts in our study. One had been treated with PFNA, while the other with Gamma 3, suggesting that there is no significant difference in the frequency of cutouts between patients treated with the two devices. In a small cohort of patients treated with a cephalomedullary implant, Baumgaertner et al (9) documented that the ideal position of the lag screw was in the centre-centre position.
The right position of the lag screw and helical blade near the centre of the femoral head and neck, in both the anteroposterior and lateral views, is critical. TAD, which represents both the position and depth of a screw in the femoral neck and head, was shown to be the most important predictive factor for the occurrence of a cutout. (12, 13) Geller et al reported a high incidence (44%) of cutouts in intertrochanteric fractures that were surgically fixed with a TAD of > 25 mm. (14) However, no fixation failure was observed in our series, possibly due to the small number of intertrochanteric fractures that were surgically fixed with a TAD of > 25 mm. No cutout was seen in patients with a TAD of < 25 mm in Geller et al's study. (14) In another study Our study demonstrated that the reduction quality of fractures treated with Gamma 3 was better than that treated with PFNA. Two factors may explain this phenomenon. One is that Gamma nail can provide better compression of bone fragments than PFNA. The other is that the helical blade of PFNA, which is inserted into the femoral neck without drilling, may push the head and neck fragment medially, leading to distraction of the bone fragments.
The ambulatory status of patients after an operation for an intertrochanteric fracture depends on different factors. (17) (18) (19) The overall walking competence was similar in patients treated with PFNA and those treated with Gamma 3. This is likely because both PFNA and Gamma 3 allow for accurate nail placement, leading to secure and stable fixation with good clinical outcomes.
In conclusion, although treatment with Gamma 3 results
in better reduction quality than PFNA, the clinical outcome of Gamma 3 is comparable to that of PFNA. Both PFNA and Gamma 3 are good intramedullary osteosynthesis for intertrochanteric fractures due to their low complication rates and good clinical results. Our conclusions, however, should be confirmed in further randomised controlled studies, as our study was undertaken prospectively, and thus may be limited due to the nature of its design.
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